AnaptysBio Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option
September 28 2018 - 4:05PM
AnaptysBio, Inc. (NASDAQ: ANAB), a clinical stage biotechnology
company developing first-in-class antibody product candidates
focused on unmet medical needs in inflammation, today
announced the closing of its underwritten public offering of
2,530,000 shares of its common stock at a public offering price of
$94.46 per share, which includes the exercise in full by the
underwriters of their option to purchase an additional 330,000
shares of common stock. Gross proceeds to AnaptysBio from the
offering are expected to be approximately $239.0 million, before
deducting underwriting discounts and commissions and offering
expenses.
Credit Suisse, J.P. Morgan and Jefferies acted as joint
book-running managers for the offering. Cantor, Guggenheim
Securities and Wedbush PacGrow acted as co-managers.
The public offering was made pursuant to a shelf registration
statement on Form S-3 that was filed by AnaptysBio with the
Securities and Exchange Commission (“SEC”) which became
automatically effective on February 5, 2018. A final prospectus
supplement and accompanying prospectus relating to and describing
the terms of the offering is available on the SEC’s website at
www.sec.gov. Copies of the final prospectus for the offering may be
obtained from Credit Suisse Securities (USA) LLC, Attention:
Prospectus Department, One Madison Avenue, New York, NY 10010, or
by telephone at (800) 221-1037, or by email at
newyork.prospectus@credit-suisse.com; J.P. Morgan Securities LLC,
Attention: Broadridge Financial Solutions, 1155 Long Island Avenue,
Edgewood, NY 11717, or by telephone at (866) 803-9204, or by email
at prospectus-eq_fi@jpmchase.com; or Jefferies LLC, Attention:
Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd
Floor, New York, NY 10022, or by email at
Prospectus_Department@Jefferies.com, or by phone at (877)
821-7388.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
Contact:Monique AllaireTHRUST
Investor Relations617.895.9511monique@thrustir.com
Chelcie ListerTHRUST Investor
Relations910.777.3049chelcie@thrustir.com
AnaptysBio (NASDAQ:ANAB)
Historical Stock Chart
From Mar 2024 to Apr 2024
AnaptysBio (NASDAQ:ANAB)
Historical Stock Chart
From Apr 2023 to Apr 2024